Skip to main content

Table 2 Modulation of the chemoresistance of cervical cancer cells by lactate

From: L- and D-lactate enhance DNA repair and modulate the resistance of cervical carcinoma cells to anticancer drugs via histone deacetylase inhibition and hydroxycarboxylic acid receptor 1 activation

Cell line

Drug

SFa

SFL

SFD

SIFL

SIFD

HeLa

NCS

0.14 ± 0.02

0.33 ± 0.01*

0.23 ± 0.04

2.37 ± 0.44

1.66 ± 0.59

HeLa

DOX

0.10 ± 0.01

0.18 ± 0.04*

0.27 ± 0.00***

1.86 ± 0.52

2.77 ± 0.29

HeLa

CDDP

0.01 ± 0.001

0.033 ± 0.001

0.027 ± 0.006*

3.37 ± 1.42

2.79 ± 0.82

Ca Ski

NCS

1.04 ± 0.05

1.54 ± 0.18

2.82 ± 0.23***

1.49 ± 0.25

2.72 ± 0.36

C33A

NCS

0.23 ± 0.03

0.35 ± 0.06

0.28 ± 0.07

1.52 ± 0.44

1.21 ± 0.45

  1. a SF survival fraction for 5 nM NCS, 100 nM DOX or 10 μM CDDP; SF L,D survival fraction after L-lactate or D-lactate pretreatment; SIF survival increase factor. The SIFs were calculated using the equation SIFlactate = SFlactate/SF; the means of at least three independent experiments are reported. Statistical significance was evaluated using one-way ANOVA followed by Tukey’s test. *P < 0.05 and ***P < 0.001 indicate significant differences between SFlactate and SF